Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer

PURPOSE: Trastuzumab is an HER2-specific agent approved as the gold-standard therapy for advanced HER2-positive (HER2+) gastric cancer (GC), but the high rate and rapid appearance of resistance limit its clinical efficacy, resulting in the need to identify new vulnerabilities. Defining the drivers i...

Descripción completa

Detalles Bibliográficos
Autores principales: Castagnoli, Lorenzo, Corso, Simona, Franceschini, Alma, Raimondi, Alessandra, Bellomo, Sara Erika, Dugo, Matteo, Morano, Federica, Prisciandaro, Michele, Brich, Silvia, Belfiore, Antonino, Vingiani, Andrea, Di Bartolomeo, Maria, Pruneri, Giancarlo, Tagliabue, Elda, Giordano, Silvia, Pietrantonio, Filippo, Pupa, Serenella M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205874/
https://www.ncbi.nlm.nih.gov/pubmed/36753044
http://dx.doi.org/10.1007/s13402-023-00769-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205874/
https://www.ncbi.nlm.nih.gov/pubmed/36753044
http://dx.doi.org/10.1007/s13402-023-00769-x

Ejemplares similares